Exhibit 10.20 BIOSANTE PHARMACEUTICALS, INC. SUBSCRIPTION AGREEMENT BioSante Pharmaceuticals, Inc. 175 Olde Half Day Road, Suite 247 Lincolnshire, IL 60069 Attn: Mr. Stephen M. Simes Ladies and Gentlemen: 1. SUBSCRIPTION. The undersigned is hereby...Subscription Agreement • June 29th, 2001 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
R E C I T A L S:Shareholders' Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Illinois
FORM C ESCROW AGREEMENTEscrow Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Ontario
EXHIBIT 10.30 INCENTIVE STOCK OPTION AGREEMENT THIS AGREEMENT is entered into and effective as of this ____ day of ____, ____ (the "Date of Grant"), by and between BioSante Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and...Incentive Stock Option Agreement • March 26th, 2004 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
CONFIDENTIALBiosante Pharmaceuticals Inc • February 24th, 2000 • Biological products, (no disgnostic substances) • Illinois
OFFICE LEASE BETWEENBiosante Pharmaceuticals Inc • March 26th, 2004 • Biological products, (no disgnostic substances)
LASALLE BANK NATIONAL ASSOCIATION, AS SUCCESSOR TRUSTEE TO AMERICAN NATIONAL BANK AND TRUST COMPANY OF CHICAGO, as Trustee under Trust Agreement dated January 1, 1991 and known as Trust No. 113370-03
FIRST AMENDMENT TO LEASELease • March 26th, 2004 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
RECITALSSublease Agreement • September 14th, 2001 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances)
BETWEENLicense Agreement • July 11th, 2000 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this "AGREEMENT"), dated as of May 6, 1999, by and among BEN-ABRAHAM TECHNOLOGIES INC., a Wyoming corporation (the "COMPANY"), and each other person executing this Agreement as set...Securities Purchase Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Illinois
Common Stock Purchase Warrant BIOSANTE PHARMACEUTICALS, INC.Biosante Pharmaceuticals Inc • December 29th, 2010 • Biological products, (no disgnostic substances)
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to shares (the “Warrant Shares”) of Common Stock.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 17th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 16, 2012, between BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
RECITALSEmployment Agreement • March 30th, 2001 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 14th, 2009 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 13, 2009, between BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
EXHIBIT 10.2 NEITHER THESE SECURITIES NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM...Biosante Pharmaceuticals Inc • May 12th, 2004 • Biological products, (no disgnostic substances)
THIS WARRANT AND THE SUBORDINATE VOTING SHARES TO BE SOLD UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED...Ben Abraham Technologies Inc • December 23rd, 1999 • Illinois
VOTING AGREEMENT ----------------Voting Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Illinois
Common Stock Purchase Warrant BIOSANTE PHARMACEUTICALS, INC.Biosante Pharmaceuticals Inc • August 17th, 2012 • Biological products, (no disgnostic substances)
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to shares (the “Warrant Shares”) of Common Stock.
RECITALSRegistration Rights Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Illinois
Exhibit 4.2 FORM OF WARRANT Warrant to Purchase Up To ______________ Shares Of Common Stock of BioSante Pharmaceuticals, Inc. THIS CERTIFIES that, for value received, ________________ ("Investor") or any transferee of Investor (Investor or such...Biosante Pharmaceuticals Inc • June 29th, 2001 • Biological products, (no disgnostic substances) • Illinois
CONFIDENTIAL Stephen M. Simes President & Chief Executive Officer BioSante Pharmaceuticals, Inc.Biosante Pharmaceuticals Inc • August 17th, 2012 • Biological products, (no disgnostic substances) • New York
EXHIBIT 10.31 NON-STATUTORY STOCK OPTION AGREEMENT THIS AGREEMENT is entered into and effective as of this ______ day of ________, ____ (the "Date of Grant"), by and between BioSante Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and...Non-Statutory Stock Option Agreement • March 26th, 2004 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Illinois
CONFIDENTIALBiosante Pharmaceuticals Inc • March 30th, 2001 • Biological products, (no disgnostic substances) • Illinois
WITNESSETH:Subscription Agreement • May 12th, 2004 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • Delaware
ARTICLE 1 INTERPRETATIONArrangement Agreement • December 23rd, 1999 • Ben Abraham Technologies Inc • Ontario
FORM OF COMMON STOCK PURCHASE WARRANT To Purchase «Shares» Shares of Common Stock of BIOSANTE PHARMACEUTICALS, INC.Biosante Pharmaceuticals Inc • August 6th, 2003 • Biological products, (no disgnostic substances) • New York
THIS IS TO CERTIFY THAT «Name», or registered assigns (the “Holder”), is entitled, during the Exercise Period (as hereinafter defined), to purchase from BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Warrant Stock (as hereinafter defined and subject to adjustment as provided herein), in whole or in part, at a purchase price of $2.15 per share, all on and subject to the terms and conditions hereinafter set forth.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 18th, 2008 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 15, 2008, is by and between BIOSANTE PHARMACEUTICALS INC. (the “Company”) and KINGSBRIDGE CAPITAL LIMITED (the “Investor”).
WARRANTBiosante Pharmaceuticals Inc • May 14th, 2004 • Biological products, (no disgnostic substances)
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 21st, 2010 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 20, 2010, between BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
1,898,735 Shares of Common Stock ANI PHARMACEUTICALS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • May 12th, 2023 • Ani Pharmaceuticals Inc • Pharmaceutical preparations • New York
ANI Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 1,898,735 shares (the “Firm Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional 284,810 shares (the “Additional Shares”) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim Securities”) is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”).
COMMON STOCK PURCHASE AGREEMENT by and between KINGSBRIDGE CAPITAL LIMITED and BIOSANTE PHARMACEUTICALS INC. dated as of December 15, 2008Common Stock Purchase Agreement • December 18th, 2008 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) is entered into as of the 15th day of December, 2008, by and between Kingsbridge Capital Limited, an entity organized and existing under the laws of the British Virgin Islands, whose business address is P.O. Box 1075, Elizabeth House, 9 Castle Street, St. Helier, Jersey, Channel Islands (the “Investor”), and BioSante Pharmaceuticals Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”).
Common Stock Purchase Warrant BIOSANTE PHARMACEUTICALS, INC.Biosante Pharmaceuticals Inc • March 4th, 2011 • Biological products, (no disgnostic substances)
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the three year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), up to shares (the “Warrant Shares”) of Common Stock.
16,000,000 Shares BioSante Pharmaceuticals, Inc. Common Stock, $0.0001 Par Value per Share UNDERWRITING AGREEMENTUnderwriting Agreement • July 28th, 2011 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
Introductory. BioSante Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 16,000,000 shares of its common stock, par value $0.0001 per share (the “Common Stock”). The 16,000,000 shares of Common Stock to be sold by the Company are collectively called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 2,400,000 shares of Common Stock as provided in Section 2. The additional 2,400,000 shares of Common Stock to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” Jefferies & Company, Inc. (“Jefferies”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the o
FORM OF NON-STATUTORY STOCK OPTION AGREEMENT (Non-Employee Director)Form of Non-Statutory Stock Option Agreement • April 4th, 2014 • Ani Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS NON-STATUTORY STOCK OPTION AGREEMENT is entered into and effective as of this day of , (the "Date of Grant"), by and between ANI Pharmaceuticals, Inc. (the "Company") and (the "Optionee").
ANI PHARMACEUTICALS, INC. AND THE BANK OF NEW YORK MELLON, as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of December 10, 2014 3.00% Convertible Senior Notes due 2019Supplemental Indenture • December 10th, 2014 • Ani Pharmaceuticals Inc • Pharmaceutical preparations
FIRST SUPPLEMENTAL INDENTURE (this “First Supplemental Indenture”) dated as of December 10, 2014 between ANI PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Company”) and THE BANK OF NEW YORK MELLON, a New York banking corporation, as trustee (the “Trustee”).
